Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV001016399 | SCV001177352 | likely benign | Hereditary cancer-predisposing syndrome | 2023-07-28 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
| Labcorp Genetics |
RCV001207625 | SCV001378987 | uncertain significance | Multiple endocrine neoplasia type 4 | 2020-02-04 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with CDKN1B-related conditions. This variant is present in population databases (rs769828807, ExAC 0.01%). This sequence change replaces proline with serine at codon 91 of the CDKN1B protein (p.Pro91Ser). The proline residue is highly conserved and there is a moderate physicochemical difference between proline and serine. |
| Sema4, |
RCV001016399 | SCV002535477 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-09-25 | criteria provided, single submitter | curation |